PT  - JOURNAL ARTICLE
AU  - Teli Liu
AU  - Chen Liu
AU  - Xiaoxia Xu
AU  - Fei Liu
AU  - Xiaoyi Guo
AU  - Nan Li
AU  - Xuejuan Wang
AU  - Jianhua Yang
AU  - Xing Yang
AU  - Hua Zhu
AU  - Zhi Yang
TI  - Preclinical Evaluation and Pilot Clinical Study of Al<sup>18</sup>F-PSMA-BCH for Prostate Cancer PET Imaging
AID  - 10.2967/jnumed.118.221671
DP  - 2019 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1284--1292
VI  - 60
IP  - 9
4099  - http://jnm.snmjournals.org/content/60/9/1284.short
4100  - http://jnm.snmjournals.org/content/60/9/1284.full
SO  - J Nucl Med2019 Sep 01; 60
AB  - Prostate-specific membrane antigen (PSMA)–targeted radioligands have played an important role in the diagnosis of prostate cancer. In this study, we developed an Al18F-labeled radiotracer and evaluated its potential for prostate cancer imaging. Methods: Al18F-PSMA-BCH (BCH is Beijing Cancer Hospital) was efficiently prepared manually. The binding affinity to PSMA was evaluated in vitro using the 22Rv1 (PSMA-positive) cell line. Small-animal PET imaging, biodistribution studies of Al18F-PSMA-BCH in mice bearing 22Rv1 and PC-3 (PSMA-negative) xenografted tumors, and a comparison with 68Ga-PSMA-617 in mice bearing LNCaP tumors were performed. PET/CT imaging was performed on 11 newly diagnosed prostate cancer patients at 1 and 2 h after injection. Biodistribution and preliminary efficacy were evaluated, and radiation dosimetry was estimated using OLINDA/EXM 2.0 software. Results: Al18F-PSMA-BCH was prepared within 30 min and was found to bind to PSMA with a dissociation constant of 2.90 ± 0.83 nM. Small-animal PET imaging of Al18F-PSMA-BCH could clearly differentiate 22Rv1 tumors from PC-3 tumors, as confirmed by ex vivo biodistribution data (7.87% ± 2.37% and 0.54% ± 0.22% injected dose/g at 1 h in 22Rv1 and PC-3 tumors, respectively). The uptake of Al18F-PSMA-BCH in 22Rv1 tumors could be substantially blocked by excess ZJ-43, a PSMA inhibitor. High-level accumulation of Al18F-PSMA-BCH was observed in PSMA-expressing organs, with increased uptake at later time points. Thirty-seven tumor lesions were detected in 11 patients, and the SUVmax in 27 lesions increased between 1 and 2 h after injection (10.60 vs. 14.11). The SUVmax in primary lesions in patients with high-risk prostate cancer was higher than that in patients with intermediate-risk prostate cancer. The kidneys received the highest estimated dose, 0.135 mGy/MBq, and the effective dose was 0.016 mGy/MBq. Conclusion: Al18F-PSMA-BCH was conveniently prepared with a reasonable yield within 30 min and showed a promising imaging capability for prostate cancer with reasonable radiation exposure. Al18F-PSMA-BCH can be used for prostate cancer imaging as a novel 18F PET radiotracer.